Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTEND-ed long-term study of BIVV001 in previously treated severe hemophilia A
CTR20210597Phase 3Active
- Sponsor
- Bioverativ Inc.
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efanesoctocog alfa in hemophilia A, sponsored by Bioverativ Inc.. Started Jun 2021; status: active.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20210597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210597.